X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1224) 1224
Publication (127) 127
Book Review (11) 11
Book Chapter (9) 9
Dissertation (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sunitinib (1004) 1004
index medicus (864) 864
humans (820) 820
oncology (688) 688
cancer (439) 439
female (426) 426
male (415) 415
tyrosine kinase inhibitor (338) 338
middle aged (333) 333
aged (306) 306
indoles - therapeutic use (303) 303
pyrroles - therapeutic use (300) 300
antineoplastic agents - therapeutic use (298) 298
metastasis (262) 262
adult (258) 258
carcinoma, renal cell - drug therapy (256) 256
endothelial growth-factor (247) 247
kidney neoplasms - drug therapy (245) 245
sorafenib (227) 227
animals (222) 222
care and treatment (222) 222
pharmacology & pharmacy (219) 219
renal cell carcinoma (207) 207
tumors (201) 201
interferon-alpha (195) 195
treatment outcome (195) 195
indoles - adverse effects (193) 193
antineoplastic agents (190) 190
pyrroles - adverse effects (190) 190
indoles - administration & dosage (188) 188
medicine & public health (188) 188
antimitotic agents (185) 185
pyrroles - administration & dosage (183) 183
angiogenesis (180) 180
su11248 (176) 176
sunitinib malate (175) 175
vascular endothelial growth factor (171) 171
chemotherapy (168) 168
renal-cell carcinoma (167) 167
antineoplastic agents - adverse effects (163) 163
carcinoma, renal cell (161) 161
bevacizumab (158) 158
analysis (153) 153
pyrroles - pharmacology (153) 153
tyrosine (153) 153
indoles - pharmacology (152) 152
therapy (149) 149
kidney neoplasms - pathology (146) 146
research (144) 144
efficacy (140) 140
survival (139) 139
antitumor-activity (138) 138
drug therapy (137) 137
angiogenesis inhibitors - therapeutic use (120) 120
aged, 80 and over (119) 119
phase-ii (118) 118
disease-free survival (111) 111
expression (111) 111
imatinib mesylate (111) 111
mice (109) 109
imatinib (108) 108
protein kinase inhibitors - therapeutic use (105) 105
targeted therapy (103) 103
urologic and male genital diseases (103) 103
carcinoma, renal cell - pathology (102) 102
antineoplastic agents - pharmacology (101) 101
cancer research (101) 101
safety (101) 101
antineoplastic agents - administration & dosage (99) 99
angiogenesis inhibitors (97) 97
everolimus (97) 97
urology & nephrology (97) 97
pharmacology/toxicology (94) 94
prognosis (94) 94
trial (94) 94
indoles - pharmacokinetics (93) 93
vegf (93) 93
neoplasm metastasis (92) 92
pyrroles - pharmacokinetics (92) 92
tyrosine kinase inhibitors (88) 88
clinical trials (87) 87
health aspects (87) 87
gastrointestinal stromal tumors - drug therapy (86) 86
kinases (86) 86
neoplasms - drug therapy (86) 86
phase-ii trial (86) 86
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
retrospective studies (82) 82
pharmacokinetics (80) 80
patients (79) 79
cell line, tumor (78) 78
hypertension (78) 78
hematology, oncology and palliative medicine (77) 77
cancer therapies (74) 74
kidney cancer (73) 73
article (71) 71
inhibitor (71) 71
niacinamide - analogs & derivatives (71) 71
carcinoma (70) 70
dose-response relationship, drug (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1206) 1206
Japanese (13) 13
French (6) 6
German (5) 5
Korean (4) 4
Chinese (3) 3
Portuguese (2) 2
Spanish (2) 2
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of Oncology, ISSN 0923-7534, 9/2008, Volume 19, Issue 9, pp. 1613 - 1618
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2009, Volume 45, Issue 11, pp. 1959 - 1968
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2012, Volume 30, Issue 2, pp. 794 - 802
Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided... 
Medicine & Public Health | Renal cell carcinoma | 2-methoxyestradiol | Clinical trials | Sunitinib malate | Oncology | Phase II | Pharmacology/Toxicology | Antiangiogenic agent | ENDOGENOUS ESTROGEN METABOLITE | APOPTOSIS | ORAL 2-METHOXYESTRADIOL | SORAFENIB | TRIAL | INTERFERON-ALPHA | THERAPY | ONCOLOGY | PATHWAY | INHIBITS ANGIOGENESIS | PHARMACOLOGY & PHARMACY | TUMOR-GROWTH | Estradiol - analogs & derivatives | United States | Colloids | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Indoles - administration & dosage | Nanoparticles | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Pyrroles - administration & dosage | Treatment Failure | Aged, 80 and over | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Drug Administration Schedule | Administration, Oral | Estradiol - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Survival Analysis | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Patient outcomes | Dosage and administration | Research | Carcinoma, Renal cell | Antineoplastic agents | Drug therapy | Studies | Angiogenesis | Pharmacology | Cancer therapies | Cancer | Index Medicus
Journal Article
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2008, Volume 134, Issue 1, pp. 51 - 57
Physiological and molecular findings indicate over-expression of HER proteins and dysregulation of neo-angiogenesis during progression of advanced prostate... 
Animal model | Sunitinib | Medicine & Public Health | Hematology | Docetaxel | Internal Medicine | Cancer Research | Oncology | Drug combinations | Cetuximab | Prostate cancer | sunitinib | METASTASIS | GROWTH-FACTOR-RECEPTOR | cetuximab | COMBINATION | CHEMOTHERAPY | drug combinations | prostate cancer | ONCOLOGY | docetaxel | ENDOTHELIAL-CELLS | TYROSINE KINASE INHIBITOR | IRINOTECAN | animal model | PHASE-I | EXPRESSION | PROGRESSION | Cell Proliferation | Humans | Neoplasms, Hormone-Dependent - secondary | Male | Gene Expression Profiling | RNA, Messenger - metabolism | Indoles - administration & dosage | Antibodies, Monoclonal, Humanized | Pyrroles - administration & dosage | Biomarkers, Tumor - metabolism | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | RNA, Messenger - genetics | Tumor Cells, Cultured - drug effects | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Prostate-Specific Antigen - blood | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Biomarkers, Tumor - genetics | Mice | Neoplasms, Hormone-Dependent - drug therapy | Analysis | Physiological aspects | Development and progression | Angiogenesis inhibitors | Hormones | Health aspects
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 7/2011, Volume 103, Issue 3, pp. 491 - 501
Receptor tyrosine kinase signaling causes profound neo-angiogenesis in high-grade gliomas (HGG). The KIT, PDGFR-α, and VEGFR2 genes are frequently amplified... 
Neurology | Sunitinib | Medicine & Public Health | Glioblastoma | KIT | PDGFR | VEGFR | Oncology | Neo-angiogenesis | VEGF RECEPTOR | BEVACIZUMAB PLUS IRINOTECAN | METASTATIC COLORECTAL-CANCER | CLINICAL NEUROLOGY | INTERFERON-ALPHA | ONCOLOGY | SINGLE-AGENT BEVACIZUMAB | TYROSINE KINASE INHIBITOR | MALIGNANT GLIOMAS | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Recurrence | Glioma - diagnosis | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Male | Antineoplastic Agents - therapeutic use | Positron-Emission Tomography | Proto-Oncogene Proteins c-kit - metabolism | Regional Blood Flow - drug effects | Glioma - pathology | Adult | Female | Pyrroles - therapeutic use | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Cerebrovascular Circulation | Disease Progression | Central Nervous System Neoplasms - pathology | Pyrrolidinones | Receptors, Platelet-Derived Growth Factor - metabolism | Indoles - therapeutic use | Aged | Central Nervous System Neoplasms - diagnosis | Central Nervous System Neoplasms - drug therapy | Glioma - drug therapy | Tyrosine | Medical research | Care and treatment | Relapse | Diseases | Complications and side effects | Chemotherapy | Gliomas | Medicine, Experimental | Brain damage | Angiogenesis inhibitors | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article